Gyre Therapeutics, Inc. (GYRE)
Free
No email, no account, no signup.
Pulling latest news for Gyre Therapeutics, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Biopharmaceuticals and anti-fibrotic therapeutics
Market Cap
$686M
We're already tracking Gyre Therapeutics, Inc. — here are the latest events we've registered
Recent News
- On May 4, 2026, the company completed the acquisition of Cullgen Inc., a clinical-stage biotech focused on targeted protein degradation, in an all-stock transaction valued at approximately $300 million. Additionally, on May 7, 2026, Gyre reported first-quarter revenue of $22.5 million and affirmed its full-year 2026 revenue guidance. In March 2026, China's NMPA granted priority review to the New Drug Application for hydronidone (F351).
Want to know how this news affects Gyre Therapeutics, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Gyre Therapeutics, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.